ANDA 76980, held by Teva Pharmaceutical Industries. Hydrochlorothiazide; Moexipril Hydrochloride.
As of Nov 22, 2026, ANDA 76980 (Moexipril Hydrochloride and Hydrochlorothiazide), held by Teva Pharmaceutical Industries, was first approved by FDA on Mar 7, 2007, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 7, 2007 | Original application | Approved | None posted |
| Moexipril Hydrochloride and Hydrochlorothiazide12.5MG;7.5MG · tablet;oral | Hydrochlorothiazide; Moexipril Hydrochloride | Rx |
| Moexipril Hydrochloride and Hydrochlorothiazide25MG;15MG · tablet;oral | Hydrochlorothiazide; Moexipril Hydrochloride | Rx |
| Moexipril Hydrochloride and Hydrochlorothiazide12.5MG;15MG · tablet;oral | Hydrochlorothiazide; Moexipril Hydrochloride | Rx |
| Aug 20, 2020 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 13, 2013 | Supplement 9Labeling | Approved | None posted |
| Dec 13, 2013 | Supplement 11Manufacturing | Approved | None posted |
| Oct 31, 2011 | Supplement 8Labeling | Approved | None posted |
| Jun 29, 2011 | Supplement 4Labeling | Approved | None posted |
| Jun 29, 2011 | Supplement 6Labeling | Approved | None posted |
| Mar 7, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters